Review of pyronaridine anti-malarial properties and product characteristics Full Text
Malaria Journal, 08/10/2012
Croft SL et al. – Pyronaridine has been developed as a fixed dose combination therapy, in a 3:1 ratio, with artesunate for the treatment of acute uncomplicated P. falciparum malaria and blood stage P. vivax malaria with the name of Pyramax(R) and has received Positive Opinion by European Medicines Agency under the Article 58 procedure.



